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Background: The objective of this prospective study was to assess the prevalence of anxiety and depression
disorders and their association with quality of life (QoL), clinical parameters and survival in patients with pulmonary
hypertension (PH).
Methods: We prospectively assessed 158 patients invasively diagnosed with pulmonary arterial hypertension
(n = 138) and inoperable chronic thromboembolic PH (n = 20) by clinical measures including quality of life
(QoL, SF-36 questionnaire), cardiopulmonary exercise testing and six minute walking distance and by questionnaires
for depression (PHQ-9) and anxiety (GAD-7). According to the results of the clinical examination and the
questionnaires for mental disorders (MD) patients were classified into two groups, 1) with moderate to severe MD
(n = 36, 22,8%), and 2) with mild or no MD (n = 122). Patients were followed for a median of 2.7 years. Investigators
of QoL, SF-36 were blinded to the clinical data.
Results: At baseline the 2 groups did not differ in their severity of PH or exercise capacity. Patients with moderate
to severe MD (group 1) had a significantly lower QoL shown in all subscales of SF-36 (p < 0.002). QoL impairment
significantly correlated with the severity of depression (p < 0.001) and anxiety (p < 0.05). During follow-up period
32 patients died and 3 were lost to follow-up. There was no significant difference between groups regarding
survival. Only 8% of the patients with MD received psychopharmacological treatment.
Conclusion: Anxiety and depression were frequently diagnosed in our patients and significantly correlated with
quality of life, but not with long term survival. Further prospective studies are needed to confirm the results.
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Pulmonary Hypertension (PH) is defined as an increase
in mean pulmonary arterial pressure (PAP) ≥25 mmHg
at rest diagnosed by right heart catheterization [1,2]. At
time of diagnosis patients are usually severely affected
with impaired exercise capacity and shortness of breath
according to WHO functional class II-IV due to elevated
pulmonary artery pressure, increased pulmonary vascu-
lar resistance and right heart failure [3-5].* Correspondence: ekkehard.gruenig@thoraxklinik-heidelberg.de
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reproduction in any medium, provided the orIn consequence, patients with PH have to manage
various life stressors, such as physical burdens, unclear
prognosis, high cost of treatment, and often unemploy-
ment, which can have a psychological impact and may
affect patients’ social contacts and relationships [6,7].
These stressors may lead to the development of mental
disorders (MD) as depression and anxiety, which have
been detected in 35% of PH-patients [6]. In this study
the most common disorders major depression and panic
disorder have been related to the degree of symptoms
and functional impairment. The prevalence of major
depression increased from 7.7% in patients with NYHA
functional class (FC) I to 45% in FC IV [6]. The prevalenceral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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NYHA FC IV. Only 24.1% of patients with PH and mental
disorders received psychopharmacological or psychothe-
rapeutic treatment [6]. Recent studies confirmed these
findings and detected major depression in 25% of PAH
patients of the REVEAL registry [8] up to 55% in PAH
patients seen in two PH referral centers in the United
States [9]. The prevalence of mental disorders in patients
with inoperable chronic thromboembolic PH (CTEPH)
has been less well assessed.
In patients with other chronic diseases as coronary artery
disease or chronic obstructive lung disease, depression was
also strongly associated with functional impairment [10]
leading to increased mortality [11].
For patients with PH it is unclear if mental disorders
as depression and anxiety lead to an impaired quality of
live and impaired prognosis and may be addressed in
therapy algorithm. Therefore, the primary objective of
our study was to examine the prevalence of mental
disorders as anxiety and depression in patients with
PAH and inoperable CTEPH who have been stable
under optimized PH-targeted medication and to analyze
its association with exercise capacity, quality of life and
survival.
Methods
Study population and design
We prospectively included patients with PAH and inop-
erable CTEPH who have been stable under optimized
PH-targeted medical treatment for at least 2 months.
Further inclusion criteria were: age between 18 and
80 years and WHO-FC I – IV. The status “inoperable
CTEPH” had been confirmed by experienced PEA-
surgeons (SG, EM). Patients had to be under optimized
medical therapy for PAH (as endothelin-antagonists, in-
haled or parenteral prostanoids, phosphodiesterase-5-
inhibitors, anticoagulants, diuretics, and supplemental
oxygen) for at least 2 months before entering the study.
The diagnosis PAH, inoperable CTEPH was established
at the participating centers according to current guide-
lines [2,5]. Patients with severe comorbidities as intersti-
tial lung disease, untreated left heart disease or known
mental disorders at the time of diagnosis by right heart
catheterization were excluded from the study. All pa-
tients underwent a detailed clinical work up including a
careful medical history asking for mental disorders,
ECG, laboratory testing with Serum N-terminal pro
brain natriuretic peptide (NTproBNP), 6-minute walking
distance under standardized conditions [12], echocar-
diography at rest and during exercise, lung function tests,
cardiopulmonary exercise testing (for exclusion of co-
morbidities) and right heart catheterization. In case of
suspected CTEPH pulmonary angiography was perfor-
med. Screening for mental disorders was performed bymedical history and using the Patient Health Question-
naire (PHQ-9) and Generalized Health Anxiety Disorder
7-item questionnaire (GAD-7). Patients were then divided
into two groups: group 1 with no or only mild MD, group
2 with moderate or severe mental disorder (PHQ-9 ≥ 10
and/or GAD-7 ≥ 10). Analysis of quality of life was perfor-
med using the short form health survey 36 (SF-36) ques-
tionnaire. The clinicians who performed clinical follow-up
assessments and treatment were completely blinded to the
results of the MD- and quality of life questionnaires. The
investigators who analysed the SF-36 questionnaires were
blinded to the results of the PHQ-9- and GAD-7-ques-
tionnaire and vice versa. Survival rate has been assessed in
2012 by phone contact or by a control visit. The investiga-
tors of the clinical data and survival rate have been
blinded to the results of the SF-36-, PHQ-9- and GAD-7-
questionnaires. Two independent investigators performed
a quality check of the database of all questionnaires. All
patients gave written informed consent for this study,
which was approved by the Ethics Committee of the Uni-
versity of Heidelberg.
Assessment of mental disorders using PHQ-9 and GAD-7
questionnaires
Both questionnaires were self-completed by the patient in
written form and refer to the symptoms of the patients
within the last 2 weeks.
The Patient Health Questionnaire (PHQ-9) was de-
veloped in 1999 as a self-reporting questionnaire
allowing a criteria-based diagnosis of depression in pri-
mary care [13]. PHQ-9 had an excellent reliability and
validity for the diagnosis of depression and consists of
the nine diagnostic criteria items measuring the severity
of depressive symptoms [14]. Spitzer et al. [15] recom-
mended categorizing the PHQ-9 total score into four
severity groups: no symptoms of depressive/anxiety disor-
ders (0–4), mild (5–9), moderate (10–14), severe (15–21)
symptoms. For our study we divided the groups in 1)
none-mild depression using the cut-off score of ≤9. Mem-
bers group 2) with moderate to severe depression had the
score ≥10.
The generalized anxiety disorder questionnaire (GAD-7)
is a self-reporting questionnaire to diagnose anxiety using
7 diagnostic items [15]. The diagnostic score of each item
of the questionnaire ranges from 0 (not at all) to 3 (nearly
every day). To estimate the severity of symptoms the total
summation score ranges from 0 to 21. The PHQ-9 is
divided into minimal (score 0–4), mild (5–9), moderate
(10–14) and severe (15–19) anxiety. The questionnaire
has a high reliability and validity for the diagnosis of major
depression [16]. For our study we divided the groups in 1)
none-mild anxiety using the cut-off score of ≤9. Mem-
bers of group 2 with moderate to severe anxiety had
the score ≥10.
Table 1 Results of GAD-7 and PHQ-9 questionnaires
Symptoms Anxiety disorder
(GAD-7)
Depression disorder
(PHQ-9)
No symptoms 11 (7.0%) 9 (5.7%)
Minimal symptoms 75 (47.5%) 62 (39.2%)
Mild symptoms 55 (34.8%) 55 (34.8%)
Moderate symptoms 13 (8.2%) 21 (13.3%)
Serious/severe symptoms 4 (2.5%) 11 (7.0%)
Daily routine difficulty
No or mild MD Anxiety or depression
disorder (moderate
to severe)
Daily routine difficulty GAD-7 (Anxiety)
n 105 32
Not difficult at all 41 (39.0%) 1 (3.2%)
Somewhat difficult 54 (51.4%) 17 (54.8%)
Very difficult 9 (8.6%) 8 (25.8%)
Extremely difficult 1 (1.0%) 5 (16.1%)
Daily routine difficulty PHQ-9 (Depression)
n 103 33
Not difficult at all 29 (28.2%) 0 (0.0%)
Somewhat difficult 62 (60.2%) 14 (42.4%)
Very difficult 11 (10.7%) 13 (39.4%)
Extremely difficult 1 (1.0%) 6 (18.2%)
Values are given as total number and %, the framing indicates the subgroup
with moderate to severe MD.
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The SF-36 consists of 36 items divided into 8 subscales:
physical functioning, role limitations relating to physical
health, bodily pain, general health perception, vitality,
social functioning, role limitation relating to mental
health, and mental health. Each question is rated on an
ordinal scale with two to six categories. The score of each
dimension is the addition of the item scores of the related
dimension further transformed to a score of 0–100, with
higher values representing better perceived health-related
quality of life [17].
Cardiopulmonary exercise testing and echocardiography
At baseline, a symptom-limited exercise test was perfor-
med during supine bicycle exercise as described pre-
viously [18]. The exercise testing began at 25 Watt (W)
with a stepwise increment of 25 W every two minutes.
Systolic pulmonary artery pressure (PASP), systolic
(RRsys) and diastolic (RRdiast) systemic blood pressures,
Work load, heart rate, minute ventilation (VE), oxygen
uptake (VO2), oxygen pulse (VO2/heart rate), and oxy-
gen saturation (SaO2) were measured continuously. The
anaerobic threshold was determined using the V-Slope
method [19]. Peak VO2 was defined as the highest 30-
second average value of oxygen uptake during the last
minute of the exercise test. Borg dyspnea index (with 6
representing no exertion and 20 maximal exertion) [20]
was inquired immediately after the test. Two-dimen-
sional and Doppler-echocardiographic recordings were
performed immediately before and during the car-
diopulmonary exercise testing using 2.5 MHz Duplex
probes and conventional equipment (Vivid 7, GE
Healthcare, Milwaukee, Wisconsin) by experienced cardiac
sonographers.
Follow-up assessment
In June 2012 all participating patients were interviewed
either by telephone or at a control visit in the
Thoraxclinic Heidelberg using a half-structured ques-
tionnaire, including structured questions also leaving
space for further clarification and remarks. The patients
were asked for present symptoms, current medication,
any further cardiac events that might have occurred
since last observation. In the situation where the index
patient was deceased, date of death was recorded and
treating physicians and/or relatives were contacted for
the cause and circumstances of death.
Statistical methods
Statistical analyses were conducted by a statistician (CF),
the results were expressed as mean ± standard deviation.
Baseline was defined as the day when the patient
completed the questionnaires. All clinical and haemo-
dynamic characteristics of patients at baseline wereanalysed by descriptive statistics. The two subgroups
were compared by two-sided Student´s t-test.
For comparison of categorical variables between
groups chi-square test was used. In case of larger tables
Craddock-Flood test and Haldane-Dawson test were
used. The Craddock-Flood Test is recommended for
large tables with small degrees of freedom and low-
frequency cells, whereas the Haldane-Dawson test is
used for contingency tables with more than five rows
and/or columns and small sample sizes.
Correlation between the MD anxiety and depression
with subscores of the SF-36 were analysed by the robust
Kendalls Tau correlation coefficient. For inner-group
comparisons non-parametric Kruskal Wallis test was
used. All tests were two sided and p-values <0.05 were
considered statistically significant. All enrolled patients
were included in the survival analysis. Survival was esti-
mated from baseline until June 2012 (the end of follow-
up in this study) by Kaplan-Meier analysis. Patients with
deaths were counted as endpoints. We analysed whether
the two groups with mild to moderate and severe MD
differed in their survival.
All analyses were performed using IBM SPSS 20 (SPSS
Statistics V20, IBM Corporation, Somers, New York).
Harzheim et al. Respiratory Research 2013, 14:104 Page 4 of 10
http://respiratory-research.com/content/14/1/104Results
Study population
We prospectively included 172 consecutive patients
diagnosed with PAH or inoperable CTEPH. Ten patientsTable 2 Study population and baseline characteristics
All patients
Patients, n 158
Gender male/female 45/133
Age, years 56 ± 16
Height, cm 167 ± 8
Weight, kg 75 ± 19
WHO functional class-no. (%)
I 1 (0.6%)
II 16 (10.1%)
III 139 (88.0%)
IV 2 (1.3%)
Diagnosis
Pulmonary arterial hypertension 129 (81.7%)
PH due to left heart disease 1 (0.6%)
PH due lung disease 6 (3.8%)
CTEPH 20 (12.7%)
other 2 (1.3%)
Cardiac catherization:
Pulmonary artery pressure [mmHg] 50 ± 17
Pulmonary vascular resistance [dyn × sec × cm-5] 873 ± 531
Pulmonary capillary wedge pressure [mmHg] 9 ± 5
Cardiac Index [l×/in/m2] 2.4 ± 0.7
Cardiac output [l/min] 4.3 ± 1.3
PAH-targeted medication
Endothelin receptor antagonists 106 (67.1%)
Phosphodiesterase-5-inhibitors 111 (70.3%)
Prostanoids inhaled 31 (19.6%)
Prostanoids intravenous 2 (1.3%)
Calcium channel blockers 37 (23.4%)
Glivec 3 (1.9%)
Riociguat 7 (4.4%)
Combination therapy
Monotherapy 50 (31.8%)
Dual therapy 72 (45.9%)
Tripletherapy 30 (19.1%)
Quadrupletherapy 2 (1.3%)
Antidepressant drug y/n 8/150
Oxygen therapy y/n 79/79
Median survival time 2.73 ± 1.12
PH = pulmonary hypertension, CTEPH = chronic throboembolic pulmonary hypertehad to be excluded due to comorbidities as severe lung
or left heart disease, 4 were excluded due to incomplete
PHQ-9 and GAD-7 questionnaires. Thus, the final study
group consisted of 158 patients (45 males, 113 females,No or mild Anxiety or depression
Mental disorder Disorder (moderate to severe)
122 36
39/83 6/30
57 ± 16 53 ± 16
168 ± 8 166 ± 8
75 ± 17 78 ± 23
5 (7.6%) 5 (8.6%)
14 (11.5%) 2 (5.6%)
106 (86.9%) 33 (91.7%)
1 (0.8%) 1 (2.8%)
100 (82.0%) 29 (80.6%)
1 (0.8%) 0 (0.0%)
5 (4.1%) 1 (4.3%)
15 (12.3%) 5 (13.9%)
1 (0.8%) 1 (2.8%)
51 ± 17 49 ± 17
865 ± 537 894 ± 520
10 ± 6 9 ± 4
2.4 ± 0.6 2.4 ± 0.8
4.3 ± 1.2 4.3 ± 1.4
78 (63.9%) 28 (77.8%)
85 (69.7%) 26 (72.2%)
24 (19.7%) 7 (19.4%)
0 (0.0%) 2 (5.6%)
28 (23.0%) 9 (25.0%)
2 (1.6%) 1 (2.8%)
6 (4.9%) 1 (2.8%)
42 (34.7%) 8 (22.2%)
52 (43.0%) 20 (55.6%)
23 (19.0%) 7 (19.4%)
1 (0.8%) 1 (2.8%)
5/117 3/33
64/58 15/21
2.91 ± 1.06 2.17 ± 1.30
nsion, y = yes, n = no.
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inoperable CTEPH).
Based on the scores of both the PHQ-9- and GAD-7-
questionnaires, patients were divided into two sub-
groups. Group 1 included 122 patients without or with
mild mental disorder (39 males and 83 females, mean
age, 57 ± 16 years) and group 2 included 36 patients with
moderate to severe anxiety and/or depression (6 malesTable 3 Cardiopulmonary exercise testing and quality of life
No o
Characteristic Total Mental
158 1
6MWD, Meter 423 ± 116 431
Cardiopulmonary exercise testing
peak VO2/kg, mL/Min/kg 12.4 ± 3.6 12.5
peak VO2, ml/min 938 ± 385 946
EqCO2 at AT, ml/min 46.3 ± 11.1 46.8
VO2 at AT, ml/min 701 ± 222 693
Oxygen pulse, (mL/min)/min-1 7.5 ± 2.2 7.4
HR rest, min-1 78 ± 14 78
HR max, min-1 123 ± 20 124
RR sys rest, mmHg 115 ± 16 116
RR dia rest, mmHg 76 ± 15 77
RRsys max, mmHg 145 ± 24 148
RR dia max, mmHg 85 ± 14 86
Oxygen saturation rest, % 94 ± 5 94
Oxygen saturation max, % 88 ± 9 88
sPAP rest, mmHg 59 ± 20 59
sPAP max, mmHg 93 ± 26 92
Workload max, W 65 ± 26 65
Borg dyspnoe 15 ± 2 14
Borg PE 15 ± 2 15
Quality of life [SF-36]
Physical functioning 37.5 ± 25.9 42.1
Physical role performance 37.4 ± 40.9 44.3
Bodily pain 70.5 ± 29.6 74.4
General health perceptions 40.3 ± 19.1 43.5
Vitality 45.5 ± 18.6 49.5
Social functioning 65.9 ± 28.8 73.9
Emotional role performance 66.4 ± 48.4 76.0
Mental health 65.9 ± 18.6 71.3
Laboratory parameters
NT-proBNP; pg/ml 1461 ± 2246 1477
Values are mean ± Standard deviation; p-values are the same for absolute value
t-test, Borg Scale: Wilcoxon Rank test 6-MWD = 6-minute walking distance, VO2
carbon dioxide, AT = anaerobic treshold HR = heart rate, RR = Blood pressure,
W = Watt.and 30 females, mean age, 53 ± 16 years) (Table 1). Thus,
within the entire group 22.8% of patients presented with
moderate to severe anxiety or depression disorder. There
were only few patients (7.0% GAD-7 and 5.7% PHQ-9)
with no signs of MD (Table 1).
Demographic data, diagnosis, functional class, hemo-
dynamic values and medical therapy of the study popu-
lation are summarized in Table 2.r mild Anxiety or depression
disorder Disorder (moderate to severe) p-value
22 36
± 118 396 ± 106 0.162
± 3.7 11.9 ± 3.2 0.414
± 412 911 ± 275 0.652
± 10.9 44.2 ± 11.5 0.309
± 229 736 ± 194 0.442
± 2.3 7.6 ± 2.2 0.693
± 12 77 ± 18 0.814
± 20 22 ± 22 0.652
± 17 110 ± 13 0.037
± 16 70 ± 9 0.019
± 24 136 ± 24 0.010
± 13 81 ± 15 0.090
± 4 95 ± 5 0.289
± 9 91 ± 8 0.075
± 20 61 ± 20 0.628
± 24 95 ± 30 0.589
± 26 65 ± 23 0.990
± 3 16 ± 2 0.043
± 2 16 ± 2 0.070
± 26.6 21.4 ± 14.6 <0.001
± 42.3 14.4 ± 25.8 <0.001
± 29.3 57.2 ± 27.1 0.002
± 19.3 30.4 ± 15.1 <0.001
± 17.5 31.7 ± 15.5 <0.001
± 25.1 39.6 ± 24.2 <0.001
± 45.1 34.4 ± 45.9 <0.001
± 15.3 47.9 ± 17.6 <0.001
± 2413 1407 ± 1539 0.873
s differences; 6MWD, Cardiopulmonary Exercise Testing: two-sided Student
/kg = max.oxygen consumption/kg, EqCO2 = Ventilatory equivalent for
sys = systolic, dia = diastolic, sPAP = systolic Pulmonary arterial pressure,
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At baseline both groups did not significantly differ in
their demographic data as age, height, weight, nor in the
severity of pulmonary hypertension as WHO-functional
class and hemodynamic parameters (Table 2). Patients
were also comparable in their PH-targeted treatment
and physical exercise capacity, measured by 6-minute
walking distance and cardiopulmonary exercise testing
(Table 3).
Gender distribution significantly differed between the
two groups (p < 0.001), with a higher proportion of
female patients in the group with moderate to severe
MD (female-to-male ratio 5:1 vs. 2.1:1).
Patients with moderate to severe anxiety and depres-
sion disorder (group 2) showed a significantly lower
quality of life in all subscales of the SF-36 questionnaire
(bodily pain p = 0.002, all other subscales p < 0.001;
Figure 1, Table 3) than patients in group 1. A correlation
between values of PHQ-9 (Depression Disorder) and
SF-36 (Quality of Life) in all 8 subscales was detected
(p < 0.001) (Figure 2). The subscales Mental health
(r = −0.51) and Vitality (r = −0.40) correlated best with
the severity of depression.
Furthermore, there was a significant correlation bet-
ween the severity of anxiety and depression disorders
(Figure 3). Patients with a higher value of the GAD-7
had also higher values in PHQ-9 (r = 0.44, p < 0.001).
Significant differences were found between the magni-
tude of anxiety or depression disorder and the subjective
daily routine difficulty. Patients with moderate-to-severe
MD reported a more difficult daily routine due to anx-
iety with the intensity very difficult to extremely difficultFigure 1 Quality of life in patients with no or only mild MD and mod
two subgroups in relation to the SF-36 Questionnaire in all subscales (p <in 9.6 vs. 41.9% (p < 0.001, Table 1). Impairment of daily
activities due to depression was even higher with 11.7 in
patients with no or mild MD vs. 57.6% in moderate to
severe MD (p < 0.001).
During cardiopulmonary exercise testing, patients in
subgroup 1 (without or with mild mental disorders) had
significantly lower mean systolic (RRsys) and diastolic
(RRdiast) systemic blood pressures at peak exercise
(RRsyst rest p = 0.04, RRdiast rest p = 0.02, RRsyst max
p = 0.01). Mean Borg Scale for dyspnea (p = 0.043) was
significantly higher in patients without MD (Table 3).
Borg Scale for peripheral exhaustion did differ between
groups in trend (p = 0.07).
Nine percent of patients with moderate to severe MD
received pharmacological treatment.
Overall 1-, 2- and 3- year survival was 96.7, 92.4
and 81.8%, respectively. There was no significant dif-
ference in survival between patients of group 1 with
no or mild MD (1-, 2- and 3- year survival 97.4, 92.9
and 82.4%) compared to patients of group 2 with
moderate to severe MD (93.9, 90.2 and 80.2%; p > 0.05)
(Figure 4).
Discussion
The results of this prospective study show for the first
time that mental disorders as anxiety and depression are
significantly associated with an impaired quality of life in
PH-patients but may not be associated with reduced sur-
vival. The study confirms the previously reported high
prevalence of mental disorders in these patients. In only
a small proportion of patients MD have been medically
treated.erate to severe MD. There was a significant difference between the
0.002).
Figure 2 Correlation between the subscales of quality of life (SF-36; y-axis) and depression disorder (PHQ-9, x-axis). There was a
significant correlation between the SF-36 subscales and depression score (p < 0.001 in all subscales). The highest correlation could be detected in
the subscales vitality (r = −0.40) and mental health (r = −0.51). A linear regression line is only shown in the subscales social functioning, vitality
and health (r-value >0.40), as only these showed evidence for a linear correlation.
Figure 3 Anxiety and depression significantly correlate in patients with PH. Generalised Anxiety disorder (GAD-7) and Depression Disorder
(PHQ-9) scales of each patient were analysed by correlation analysis. Score values significantly correlated (r = 0.44, p < 0.001) between groups.
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Figure 4 Survival amongst PH patients according to mental disorder. The two groups did not sigificantly differ in their survival (p > 0.05).
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quality of life
Patients with moderate to severe mental disorder (group 2)
had a significantly lower quality of life shown in all sub-
scales of SF-36. Despite promising new medical treatment
options, QoL still constitutes one of the main treatment
goals of PH therapy [21]. By proving a strong association
of MD with QoL in PH patients, our study highlights the
importance of taking MD into account in clinical mana-
gement of PH patients. Previously the association of MD
with QoL has been proven in several other diseases, as in
cystic fibrosis [22], diabetes mellitus [23], heart diseases
[24] or even in community dwelling adults [25]. Several
authors come to the conclusion to treat MD in order to im-
prove QoL [22-25]. For example, in patients with left heart
failure, remission of depression led to an increase in quality
of life, 6-minute walking distance and social function [26].
In our patients, the occurrence of MD was associated with
a higher perceived difficulty of performing daily activities.
However it is not clear, whether this is a result of MD or a
possible reason for the development of MD.
Corresponding to this finding, our data showed a
higher perceived exertion in moderate to severe MD
measured by Borg Scale, though maximal workload
during ergometer test did not significantly differ
between groups. As both subgroups did not differ in
their physical exercise capacity this might be a hint
for a different perception of the patients’ abilities and
limitations independent of the patients’ exercise capacity.
This phenomenon has to be further investigated.
The association between physical exercise capacity and
quality of life has recently been shown for PAH and
CTEPH [27].High prevalence of MD in PAH/CTEPH
This prospective study confirms the previously reported
high prevalence of mental disorders in PAH [6,9,28-30]
and shows a similar prevalence for inoperable CTEPH
patients. The rate of moderate to severe major depres-
sive disorder in PAH has been estimated to be 20%-50%
[9,29,31] and was similar to the prevalence in patients
with left-heart failure (30% major depression) [32]. In
our study a female predominance was detected among
PAH patients with depression or anxiety disorder (male
13.3 vs. female 26.5%) corresponding to a previously de-
scribed higher likelihood of women being diagnosed
with MD [33,34]. Due to the severity of the disease, pul-
monary hypertension is thought to produce emotional
responses of anxiety, depression and panic attacks [35].
Mental disorders and treatment in PH
Only a few studies have assessed the effects of treatment
of depression or anxiety in patients with pulmonary
hypertension. Patients treated with epoprostenol had a
lower rate of depression and anxiety compared to pa-
tients whithout this treatment [29]. This finding suggests
that improvement of PAH-driven symptoms by PAH-
targeted medical therapy or by a specialized training
program [18] may improve the comorbidity with anxiety
and depression. However, clinical significance and optimal
therapy strategy of MD in patients with PH are unclear. In
patients with left heart failure, remission of depression led
to an increase in quality of life, 6-minute walking distance
and social function [26]. A study investigating the effect of
antidepressant medication on morbidity and mortality in
depressed patients after myocardial infarction showed a
slightly reduced cardiovascular mortality [36]. In our
Harzheim et al. Respiratory Research 2013, 14:104 Page 9 of 10
http://respiratory-research.com/content/14/1/104study, the clinicians who treated the patients were blinded
to the results of the MD-targeted questionnaires. There-
fore, in many patients of the study the participating
clinicians may have overseen the MDs. In fact 91% of our
patients with moderate-to-severe MD were not receiving
psychopharmacological treatment. Similar observations
have previously been made with 75% of PH-patients with
mild-to-severe depression not receiving antidepressant
therapy [9]. Taking into account that the manifestation of
MD was highly correlated with a reduced quality of life,
we can conclude that there is still a lack of psychosocial
support for PH patients. However, the impact of counsel-
ing and integration of psychosocial support and pharma-
cological treatment of patients with PH have to be further
investigated by randomized controlled trials. In addition,
long term data have to be assessed in order to investigate
the cause of MD, as it is not clear, whether a decrease in
QoL or MD develops first during the clinical course of the
disease. Attention to MD in any patient population seems
to be useful, but it’s not clear that an association suggests
causality, and in fact it may well be that it is the QoL
limitations which produce anxiety and depression.
From our clinical experience exercise training as add-
on to medical therapy, which has been effective to
improve work capacity, quality of life and further prognos-
tic relevant parameters in patients with PH [18,37-40],
may also be helpful to improve depression and anxiety. In
patients with coronary artery disease exercise training
improved depressive symptoms and survival [41]. There-
fore, it might also be worth to investigate the effect of this
add-on treatment on MD in PH.
Mental disorders in PH and survival
Despite no specific treatment of MD in the majority of
patients, our study did not detect a significant difference
in survival between patients with no or mild MD com-
pared to patients with moderate to severe MD. So far, it
is still uncertain whether depressive episodes in patients
with PH, as in reactive depression, are mechanisms be-
longing to the phases of coping. However, in this study
we did not obtain follow-up data of the patients’ clinical
and mental course. It is possible that mental disorders
obtained within the study have improved during follow-
up or may have been treated at a later stage. Therefore,
the data of this study are not conclusive regarding the
association of MD with survival or time to clinical
worsening.
Conclusion
Anxiety and depression were frequently diagnosed in
patients with PAH and inoperable CTEPH despite opti-
mized medical PH-treatment and significantly correlated
with a reduced quality of life. Most patients did not
receive psychopharmacological treatment. MD in PHappears to be not only underdiagnosed but also under-
treated. The results of this study suggest that a screening
for MD in PH-patients using specific questionnaires
should be integrated in clinical practice. Further ran-
domized controlled studies are needed to assess the
effect of specific MD-targeted treatment on quality of
life and survival in PH-patients.
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